שולי רווח תפעולי ממכירות: Innate Pharma SA (IPHA)

Risks for Innate Pharma S.A. (IPHA) are linked to its dependence on the success of joint NK projects with pharmaceutical behemoths. The operating margin trend captures these fluctuations, with this metric standing at -1257.00. Stability is provided by the ownership of unique antibody patents, which grants the company significant pricing power. The issuer's revenues are based on lucrative licensing payments and upfronts from the world's largest corporations.
Innate Pharma S.A. - פילוחים אנליטיים ומדדי מפתח (IPHA)

For Innate Pharma S.A. (IPHA), the efficiency of cancer immunotherapy development correlates directly with the operating margin. This metric is calculated as the ratio of operating profit to revenue, excluding the impact of taxes and debt obligations. By analyzing the operating income margin, an investor can discern the actual profitability of the core business. Geopolitical barriers and logistical collapses in the procurement of biomaterials may temporarily depress this metric. Stable growth of this indicator confirms the company's resilience to external shocks.